Zenas BioPharma, Inc.
ZBIONASDAQHealthcareBiotechnology
Previous close
$32.29
+$0.67 · +2.12%
ZBIO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
52
Fair Value
Momentum
64
Gaining
Sentiment
37
Bearish
Risk resilience
48
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteZenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Leon Oliver Moulder Jr.
- Listed since
- Sep 13, 2024
- Employees
- 167
Market position
Day range
Current $32.29
52-week range
Current $32.29
- Open
- $31.83
- Previous close
- $31.62
- Volume
- 808.72K
- 1.08× average
- Average volume
- 746.47K
- Average daily volume
- Market cap
- 2.04B USD
- Beta
- -1.01
- Market reference 1
- 50-day average
- $28.0816
- +14.99% above average
- 200-day average
- $26.0451
- +23.98% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.59B USD
- P/E (TTM)
- -3.36×
- P/B (TTM)
- 8.25×
- P/S (TTM)
- 2,038.58×
- EV / EBITDA
- -4.3×
- Earnings yield
- -23.26%
- Free cash flow yield
- -10.61%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -5972.60%
- Operating margin
- -47557.30%
- Net margin
- -48438.40%
- Return on equity
- -156.00%
- Return on assets
- -98.46%
- Return on invested capital
- -65.61%
Financial health
- Debt / equity
- 0.91×
- Current ratio
- 5.61×
- Altman Z-score
- -0.36
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 10M USD | 5M USD | 50M USD | — |
| Cost of goods sold | — | 139.14M USD | — | 61.69M USD |
| Gross profit | 10M USD | −134.14M USD | 50M USD | −61.69M USD |
| Research and development | 168.06M USD | 139.14M USD | 60.03M USD | 62.69M USD |
| Selling, general, and administrative | 53.32M USD | 29.75M USD | 17.11M USD | 13.51M USD |
| Operating expenses | 221.39M USD | 29.75M USD | 87.15M USD | 14.51M USD |
| Interest income | 12.15M USD | — | — | — |
| Interest expense | 7.33M USD | — | — | — |
| Depreciation and amortization | 56K USD | 137K USD | 113K USD | 78K USD |
| Operating income | −211.39M USD | −163.89M USD | −37.15M USD | −76.2M USD |
| Net income | −377.74M USD | −156.99M USD | −37.12M USD | −119.28M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 25%
- 2 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -52.31%
- 8 comparable reports
- Latest EPS result
- -1.77
- Estimate -1.12 · Miss by 58.04%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$32.00
0.90% downsideRating distribution
5 ratingsRecent analyst actions
ZBIO news
ZBIO peers
ETFs holding ZBIO
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI44.79M0.39%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI28.02M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM23.19M0.03%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF13.71M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO8.46M0.06%15.16B USD0.24%$387.37+1.24%
iShares Biotechnology ETFIBB7.57M0.07%10.75B USD0.44%$213.56+1.29%
Schwab U.S. Small-Cap ETFSCHA5.68M0.02%23.1B USD0.03%$34.83+0.52%
Vanguard Russell 2000 ETFVTWO5.02M0.03%17.4B USD0.06%$121.25+0.74%State Street SPDR S&P Biotech ETFXBI- Market value
- 44.79M
- Weight
- 0.39%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 28.02M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 23.19M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 13.71M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 8.46M
- Weight
- 0.06%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
iShares Biotechnology ETFIBB- Market value
- 7.57M
- Weight
- 0.07%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 5.68M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Vanguard Russell 2000 ETFVTWO- Market value
- 5.02M
- Weight
- 0.03%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Continue in GoAI
Research ZBIOresearch.disclaimer